Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Overview Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Companies Involved in Therapeutics Development Amgen Inc Amorepacific Corp BCN Peptides SA Centrexion Therapeutics Corp Daewoong Pharmaceutical Co Ltd DoNatur GmbH Flex Pharma Inc Grunenthal GmbH Kyowa Hakko Kirin Co Ltd Medifron DBT Co Ltd Neurim Pharmaceuticals Ltd Pila Pharma AB Sylentis SAU Toray Industries Inc Vitality Biopharma Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Drug Profiles AMG-986 - Drug Profile Product Description Mechanism Of Action R&D Progress CA-008 - Drug Profile Product Description Mechanism Of Action R&D Progress CA-011 - Drug Profile Product Description Mechanism Of Action R&D Progress CA-016 - Drug Profile Product Description Mechanism Of Action R&D Progress cannabidiol - Drug Profile Product Description Mechanism Of Action R&D Progress capsaicin - Drug Profile Product Description Mechanism Of Action R&D Progress capsaicin - Drug Profile Product Description Mechanism Of Action R&D Progress CMX-020 - Drug Profile Product Description Mechanism Of Action R&D Progress DD-04107 - Drug Profile Product Description Mechanism Of Action R&D Progress DWP-05195 - Drug Profile Product Description Mechanism Of Action R&D Progress FLX-787 - Drug Profile Product Description Mechanism Of Action R&D Progress FLX-788 - Drug Profile Product Description Mechanism Of Action R&D Progress FLX-797 - Drug Profile Product Description Mechanism Of Action R&D Progress FLX-798 - Drug Profile Product Description Mechanism Of Action R&D Progress K-685 - Drug Profile Product Description Mechanism Of Action R&D Progress MCS-18 - Drug Profile Product Description Mechanism Of Action R&D Progress MDR-16523 - Drug Profile Product Description Mechanism Of Action R&D Progress MDR-652 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies to Inhibit TRPV1 for Inflammatory Pain and Cancer Pain - Drug Profile Product Description Mechanism Of Action R&D Progress MTX-071 - Drug Profile Product Description Mechanism Of Action R&D Progress NEO-6860 - Drug Profile Product Description Mechanism Of Action R&D Progress NeuP-12 - Drug Profile Product Description Mechanism Of Action R&D Progress PAC-14028 - Drug Profile Product Description Mechanism Of Action R&D Progress Peptides to Target TRPV1 for Pain and Itch - Drug Profile Product Description Mechanism Of Action R&D Progress piromelatine - Drug Profile Product Description Mechanism Of Action R&D Progress QX-314 - Drug Profile Product Description Mechanism Of Action R&D Progress resiniferatoxin - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Block TRPV1 for Congestive Heart Failure and Cardiomegaly - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Block TRPV1 for Pain - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Block TRPV1 for Pain - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate TRPV1 Channel for Pain and Inflammation - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate TRPV1 for Demyelinating Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Block TRPV1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress tivanisiran - Drug Profile Product Description Mechanism Of Action R&D Progress XEND-0501 - Drug Profile Product Description Mechanism Of Action R&D Progress zucapsaicin - Drug Profile Product Description Mechanism Of Action R&D Progress Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Dormant Products Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Discontinued Products Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Product Development Milestones Featured News & Press Releases Jan 30, 2018: Revive Therapeutics Advances Research Program of Cannabinoid-Based Therapies Targeting Liver Diseases Jan 16, 2018: Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain Jan 02, 2018: Centrexion Therapeutics Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018 Dec 07, 2017: Concentric Analgesics Receives FDA Fast Track Designation for CA-008 for Post-Surgical Pain Nov 28, 2017: Enrollment Completed in Flex Pharmas Phase II Exploratory Spasticity Study in MS Nov 06, 2017: Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in ALS Nov 02, 2017: Concentric Analgesics Launches CA-008 Clinical Development Program in Post-Surgical Pain Oct 30, 2017: Centrexion Therapeutics Announces Multiple Data Presentations on CNTX-4975 at the American College of Rheumatology Annual Meeting 2017 Oct 30, 2017: NEO6860 Phase II Data to be Presented at the American College of Rheumatology’s Annual Meeting Oct 19, 2017: The World Health Organization Selects Tivanisiran as the International Nonproprietary Name for SYL1001 Oct 16, 2017: Flex Pharma Initiates CMT Phase 2 Trial with FLX-787 in US Sep 27, 2017: Revive Therapeutics Applies to FDA for Orphan Drug Designation for Treatment of Autoimmune Hepatitis Sep 26, 2017: Centrexion Therapeutics to Present Phase 2b data of Osteoarthritis Drug Candidate CNTX-4975 at the 11th Annual Pain and Migraine Therapeutics Summit Aug 29, 2017: Centrexion Therapeutics to Present 6-Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at PAINWeek 2017 Aug 01, 2017: Flex Pharma Initiates ALS Phase 2 Trial with FLX-787 in US Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indications, H1 2018 Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018 Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products under Development by Companies, H1 2018 (Contd..1) Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 (Contd..1), H1 2018 Products under Development by Companies, H1 2018 (Contd..2), H1 2018 Products under Development by Companies, H1 2018 (Contd..3), H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Amgen Inc, H1 2018 Pipeline by Amorepacific Corp, H1 2018 Pipeline by BCN Peptides SA, H1 2018 Pipeline by Centrexion Therapeutics Corp, H1 2018 Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018 Pipeline by DoNatur GmbH, H1 2018 Pipeline by Flex Pharma Inc, H1 2018 Pipeline by Grunenthal GmbH, H1 2018 Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018 Pipeline by Medifron DBT Co Ltd, H1 2018 Pipeline by Neurim Pharmaceuticals Ltd, H1 2018 Pipeline by Pila Pharma AB, H1 2018 Pipeline by Sylentis SAU, H1 2018 Pipeline by Toray Industries Inc, H1 2018 Pipeline by Vitality Biopharma Inc, H1 2018 Dormant Products, H1 2018 Dormant Products, H1 2018 (Contd..1), H1 2018 Dormant Products, H1 2018 (Contd..2), H1 2018 Dormant Products, H1 2018 (Contd..3), H1 2018 Dormant Products, H1 2018 (Contd..4), H1 2018 Discontinued Products, H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Top 10 Routes of Administration, H1 2018 Number of Products by Stage and Top 10 Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

Amgen Inc Amorepacific Corp BCN Peptides SA Centrexion Therapeutics Corp Daewoong Pharmaceutical Co Ltd DoNatur GmbH Flex Pharma Inc Grunenthal GmbH Kyowa Hakko Kirin Co Ltd Medifron DBT Co Ltd Neurim Pharmaceuticals Ltd Pila Pharma AB Sylentis SAU Toray Industries Inc Vitality Biopharma Inc